Joshi Gaurav, Poduri Ramarao
School of Pharmacy, Graphic Era Hill University, Dehradun, India.
GITAM Institute of Pharmacy, GITAM University, Visakhapatnam, India.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2034458. doi: 10.1080/21645515.2022.2034458. Epub 2022 Mar 3.
The reply letter has been put forth in response to the comment made by Karthyayani Priya Satish entitled "India and the COVID-19 Vaccine." The comment was made in context to our published work "Exploring the covid-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?" The reply letter is concerned with the newer variant of SARS-CoV-2, i.e., Omicron and its impact on severity and vaccine efficacy. Though the variant is mild, as per the reports, the cases are rising at an unprecedented rate that may create havoc on humankind considering shortages of RT-PCR testing and prevailing unequal vaccine distribution and vaccine hesitancy.
这封回复信是对卡尔蒂亚亚尼·普里亚·萨蒂什题为《印度与新冠疫苗》的评论做出的回应。该评论是针对我们发表的论文《探索针对严重急性呼吸综合征冠状病毒2及其变种的新冠疫苗候选物：我们的现状与未来方向》。回复信关注的是严重急性呼吸综合征冠状病毒2的新变种，即奥密克戎及其对疾病严重程度和疫苗效力的影响。尽管据报道该变种症状较轻，但鉴于逆转录聚合酶链反应检测的短缺、当前不平等的疫苗分配以及疫苗犹豫现象，病例正以前所未有的速度增加，这可能会给人类带来巨大破坏。
